Shopping Cart
- Remove All
- Your shopping cart is currently empty
MK-1084, a selective KRAS G12C inhibitor, is currently in a Phase I clinical trial (NCT05067283). It demonstrates anticancer activity and can be utilized alone or in combination with pembrolizumab for cancer research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | MK-1084, a selective KRAS G12C inhibitor, is currently in a Phase I clinical trial (NCT05067283). It demonstrates anticancer activity and can be utilized alone or in combination with pembrolizumab for cancer research [1]. |
Molecular Weight | 637.08 |
Formula | C32H31ClF2N6O4 |
Cas No. | 2641216-67-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.